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mechanisms for ALK break positive cases are gatekeeper mutations in the ALK gene. Also activation
of the EGFR pathway, KRAS mutations, the autophagy pathway and epithelial mesenchymal transition
(EMT), have been associated with resistance. Many of the proposed resistance mechanisms need to be
functionally studied to proof a causative relationship with resistance.
© 2016 The Authors. Publis
Table 1
Overview of drugs used as EGFR-TKI or ALKi and their most important targets.
Drugs Targets
Afatinib EGFR, HER2, HER3, HER4














































erlotinib.HER2ampliﬁcationsandmutationswereobserved in lungCrizotinib MET, ALK, ROS1
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. Introduction
Patients with an activating mutation in the epidermal growth
actor receptor (EGFR) gene, e.g. deletion in exon 19 or L858R
utation, occur in about 8% of non-small cell lung cancer (NSCLC)
atients (Kerner et al., 2013). In more than 70% of patients treat-
ent is successful with EGFR-tyrosine kinase inhibitors (TKIs).
owever, resistance following treatment with TKIs eventually
merge in all of these patients. Most clinical data have been gath-
red with the ﬁrst generation reversible EGFR inhibitors geﬁtinib
nd erlotinib (Table 1).
Second-generation EGFR-TKIs, e.g. afatinib and dacomitinib,
orm covalent irreversible bonds with the target that may increase
heir effectiveness through a more effective inhibition of EGFR
ignaling. At thismoment also 3rd generation TKIs are under inves-
igation in phase III studies, e.g. osimertinib and rociletinib, for
atients with a EGFR T790M mutation, because these TKI bind
ore speciﬁc to this altered tyrosine kinase binding pocket (Jänne
t al., 2015; Sequist et al., 2015). Around ﬁve percent of NSCLC
atients showed to have a chromosomal inversion involving the
chinoderm Microtubule-associated protein-Like 4 (EML4) gene
nd the Anaplastic Lymphoma Kinase (ALK) gene These patients
an be treated with ALK inhibitors (ALKi), e.g. crizotinib and ceri-
inib (Table 1) (Kwak et al., 2010). At this moment alectinib only
as only been approved in Japan. Ceritinib and alectinib bind more
peciﬁc with the tyrosine kinase of pocket of the ALK protein due
o covalent binding and the fact that these are smaller molecules
han crizotinib. The median time to progression is 8–12 months for
ll TKIs when administered as ﬁrst-line treatment, which is bet-
er than chemotherapy (Mok et al., 2009; Rosell et al., 2012; Shaw
t al., 2013; Sequist et al., 2013). The median progression free sur-
ival (PFS) is comparable to ﬁrst line treatment when these TKIs
re used as second-line treatment following chemotherapy (Mok
t al., 2013). In subsequent treatment lines however survival is not
ifferent from chemotherapy.
Many genetic aberrations have been described as possible
echanisms for resistance towards TKIs (Rosell et al., 2013). In this
eview we will focus on resistance mechanisms, found in tumor
iopsies of NSCLC patients, xenograft models and cell lines that
merge after treatment with or exposure to EGFR-TKI afatinib
Boehringer Ingelheim GmbH, Germany) and the ALKi crizotinib
Pﬁzer Inc., City of New York, NY). Both afatinib and crizotinibhed by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
have only recently been approved for treatment and knowledge
on known and possible resistance mechanisms is essential for cli-
nicians.
2. Resistance after EGFR tyrosine kinase inhibitors
Afatinib, erlotinib and geﬁtinib are registered as ﬁrst line treat-
ment for patients with advanced NSCLC with activating EGFR
mutations. Afatinib is the only proven drug showing an increased
overall survival as ﬁrst line treatment in patients with an exon 19
deletion as compared to chemotherapy, i.e. 31.7 (95% conﬁdence
interval (CI) of 28.1–35.1) vs. 20.7 (95% CI of 16.3–25.6) months,
respectively (Miller et al., 2012; Yang et al., 2015). For patients
with a L858R mutation OS however is comparable between afa-
tinib and chemotherapy treatment (OS 22.1 months for afatinib;
95% CI of 19.6–25.4 vs. 26.9 months for chemotherapy; 95% CI of
23.2–31.7) (Yang et al., 2015). An overview of currently known
resistance mechanisms is given below. It consists of a summary
of ﬁndings with ﬁrst generation TKIs followed by a more extensive
overview of resistance mechanisms associated with afatinib only.
2.1. Erlotinib and geﬁtinib resistance in NSCLC patients, cell lines
and mouse models
The T790M mutation is the most common observed resis-
tancemechanism (30–83%) in patients treatedwithﬁrst generation
EGFR-TKIs (Arcila et al., 2011; Chen et al., 2009; Hata et al., 2013;
Su et al., 2012; Yu et al., 2013; Lee et al., 2014). The resistant
tumor clones may originate from a minor pre-existing T790M
mutation positive tumor cell subclone or present as a de novo
mutation (Nguyen et al., 2009). Mutation screening of >2700 lung
pre-treatment cancer samples with an EGFR mutation revealed a
T790M mutation in only 20 cases. This may indicate that without
TKI selective pressure the frequency of the T790M is very low (Yu
et al., 2014a). The T790M mutation has also been described as a
germ line variant co-segregating in a family with the development
of lung adenocarcinoma (Oxnard et al., 2012; Yu et al., 2014b). A
similar co-segregation with lung cancer was seen in a family car-
rying a germ line V843I and a family with a P848L EGFR mutation
(Matsushima et al., 2014; Ohtsuka et al., 2011; Prim et al., 2014). It
is thereforemost likely that resistantmutations are already present
in minor clones of the tumor. In a clinical subgroup analysis of
EGFR mutant patients in the EURTAC trial pretreatment T790M
mutation was associated with a decrease in PFS. Bcl-2 interac-
ting mediator of cell death (BCL2L11, also known as BIM) mRNA
expression was associated with longer PFS and OS in the same
patients treated with erlotinib (Costa et al., 2014). Mice, with lung
epithelial cell speciﬁc overexpression of activated EGFR that devel-
oped lung tumors and who were treated with erlotinib, revealed
a T790M mutation in 5/17 and in 5/17 different mice a MET gene
ampliﬁcation (Politi et al., 2010). Indicating that both T790M and
MET gene ampliﬁcation are potential resistance mechanisms tocancer biopsies in respectively 10% and 2% of tumors with acquired
resistance to erlotinib and geﬁtinib, but only in 1% of untreated
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esponsible for resistance emerging under pressure of treatment
speciallywith erlotinib. Phosphorylationof Src family kinase (SFK)
as identiﬁed in tumor samples of patients treatedwithﬁrst gener-
tion TKIs (Yoshida et al., 2014). Additional resistance mechanisms
uch as expression of HGF, the ligand for MET or increased activa-
ion of the AXL pathway, up-regulation of NF-kB, GAS6, ADAM17,
OTCH1, p53, Wnt and mTor were reported in studies focusing on
umor samples and cell lines (Rosell et al., 2013; Zhang et al., 2012;
uang et al., 2011; Baumgart et al., 2010; Fong et al., 2013; Bivona
t al., 2011; Chen et al., 2013a).
.2. Afatinib resistance in NSCLC patients
In Asian patients the presence of T790M mutations in re-
iopsies obtained before second line treatment with afatinib
reatment had no prognostic or predictive role (Sun et al., 2013a).
his observation was conﬁrmed in a study where a combination
f afatinib and cetuximab (a monoclonal antibody against EGFR)
howed tumor responses irrespective of the presence of T790M
Table 2) (Janjigian et al., 2014). Thus questioning as to whether
T790M mutation is important as a resistance mechanism upon
reatment with afatinib. Afatinib is equally potent against wild-
ype EGFR and EGFR T790M and therefore side effects resulting
rom inhibiting wild-type EGFR (rash and diarrhea) prevents the
uppression of T790M tumor cells at clinically achievable doses.
n addition, patients treated with afatinib have more side effects,
.g. diarrhea and skin rash, than observed with erlotinib or geﬁt-
nib treated patients (Takeda et al., 2015). Third generation EGFR
KIs such as rociletinib, osimertinib, or EGF816, targetmutant EGFR
790M and largely spares wild type EGFR, thereby decreasing tox-
city and therefore permit clinical doses that fully suppress T790M.
hat explains their efﬁcacy in T790M positive tumors.
.3. Afatinib resistance in cell lines, xenografts and mouse models
.3.1. Gatekeeper mutations
Multiple cell lines have been used in the search for respon-
iveness and resistance mechanisms to afatinib. A summary of the
ndogenous and exogenous alterations in relation to TKI respon-
iveness is given in Table 3.
Cell lines carrying the activating exon19delE746 A750or L858R
utations are sensitive to afatinib (Matsushima et al., 2014). PLA1
ells with the activating L858R in combination with the resistant
843I mutation are more resistant to afatinib than H1975 cells
ith a L858R in combination with the T790M resistant mutation.
his difference in sensitivity can be explained by conformational
hange of the predicted TKI binding site as a consequence of the
843I and the T790M mutations (Matsushima et al., 2014). Both
GFR mutations are referred to as gatekeeper mutations, of which
843I appears tobeamore resistant variant thanT790M. Inanother
tudy afatinib inhibits the growth of the H1975 cell line (contain-
ng the L858R/T790M mutation) in vitro as well as in the xenograft
odel (Li et al., 2008). In comparison to EGFR-TKIs, EGFR siRNAs
ere much more effective in growth inhibition of lung cancer cells
Chen et al., 2012). This enhanced efﬁciency occurred especially in
790M mutation positive lung cancer cell lines (Chen et al., 2013b).
his indicates that treatment with EGFR-TKIs only partly block the
GFR signaling pathway, in which especially T790M seems to be
mportant as a resistance mechanism in cell lines.
Resistance upon exposure to afatinib in PC9 cells seems to
e irreversible indicating that the resistance has been caused
y a genetic change (Kim et al., 2012a). The majority of the
esistant subclones remained dependent on EGFR signaling as
hown by siRNA treatment. These EGFR dependent PC9 clones all
ained a T790M mutation and cell viability was dependent of the
790M allele dosage (Kim et al., 2012a). However, in the xenograftcology/Hematology 100 (2016) 107–116 109
model no difference in tumor response was observed at maxi-
mum dose for afatinib between different T790M allele dosages.
Other known resistance mechanisms such as ampliﬁcation of MET,
deletion of phosphatase and tensin homolog (PTEN) and epithelial-
mesenchymal transition (EMT), were not observed in the afatinib
resistant, EGFR independent PC9 subclones.
In a mouse model, overexpression of L858R mutant EGFR in
epithelial lung cells resulted in the development of lung cancer
(Politi et al., 2010). Upon treatment of these mice with erlotinib,
resistant tumor clones gained a T790M mutation, which showed a
modest response to afatinibmonotherapy. Combining afatinibwith
cetuximabgreatly enhanced the responsewith complete responses
in most cases (7/8) (Regales et al., 2009). This indicates that adding
cetuximab to afatinib induces a higher response rate in T790M
positive tumor cells. Another study suggested that this effect was
related to theheterodimerizationof tyrosine-phosphorylatedEGFR
withHER2, towhich afatinib is a known inhibitor aswell (Takezawa
et al., 2012). The differences observed between the cell line and
mouse models in comparison to the above-discussed ﬁndings in
patient samples are caused by differences in clinical achievable
afatinib doses. Such afatinib doses are too low to suppress T790M
mutated tumors.
2.3.2. HER2 gene expression and receptor involvement in
resistance
Knockdown of HER2 in PC9, HCC827 and H3255 cells increased
sensitivity to afatinib (Takezawa et al., 2012). This is consistent
with the improved response rate observed in patients treated
with afatinib and cetuximab as compared to erlotinib and cetux-
imab or afatinib alone. Erlotinib-resistant PC9 and HCC827 derived
xenograft tumors are characterized by enhanced levels of phos-
phorylated HER2. Proliferation of these HER2 positive tumor cells
in nude mice could be inhibited by afatinib or cetuximab, with the
strongest inhibition ofHER2being observed for treatmentwith afa-
tinib/cetuximab (Takezawa et al., 2012). ThusHER2 is amechanism
of resistance induced upon treatment with erlotinib and geﬁtinib.
For afatinib however, a known pan-HER inhibitor, this mechanism
is not relevant.
2.3.3. MET gene expression and receptor involvement in
resistance
Ampliﬁcation and/or mutations of MET have been identiﬁed in
twoof the lungcancer cell lines andmayrepresent apossible escape
mechanism to afatinib. Treatment of lung cancer cell lines harbor-
ing activating EGFR mutations with crizotinib (a known MET and
ALK inhibitor) showed a marked inhibitory effect on cell growth
of MET ampliﬁcation positive cell lines, indicating that these cells
were addicted to the MET pathway. The MET addiction was con-
ﬁrmed by increased levels of apoptosis upon MET inhibition in
MET ampliﬁcation positive cell lines, EBC-1 and H1993 (Chen et al.,
2013b; Tanizaki et al., 2011). EGFR mutation positive cell lines with
mutant or wild type MET were not or less sensitive to crizotinib
and/or MET siRNAs, indicating that a MET mutation is not impor-
tant in resistance in these cells (Chen et al., 2013b; Tanizaki et al.,
2011). Combination of MET siRNAs with either EGFR-TKIs, includ-
ing afatinib, or EGFR siRNAs, revealed decreased proliferation as
compared to EGFR siRNA alone (Chen et al., 2013b). In the T790M
positive H1975 cell line, the synergistic effect was modest, also
when the MET siRNA was combined with a siRNA directed speciﬁ-
cally against T790M. Concomitant treatment of the cell lines with
a MET inhibitor (SU11274) caused increased sensitivity for geﬁti-
nib, erlotinib, afatinib or cetuximab, especially for the H1975 cells.
The combined effect was most pronounced for the combination
of SU11274 and afatinib (Chen et al., 2009). In mice models, EGFR
knock down in MET ampliﬁcation positive tumors increased tumor
cell death upon treatment with MET inhibitors. Mutations in MET
110 A.J. van der Wekken et al. / Critical Reviews in Oncology/Hematology 100 (2016) 107–116
Table 2
Overview of re-biopsy studies in patients treated with afatinib.
Re-biopsy study N Mutation analysis Treatment mutations PFS (mo) reference
Sun et al. (2013) 70 direct sequencing and sequencing
using a peptide nucleic acid
afatinib T790M+ 14.7 Sun et al. (2013a)
T790M− 14.1
Janjigian et al. (2014) 126 NA/different methods afatinib/cetuximab T790M+ 4.6 Janjigian et al. (2014)
T790M− 4.8
Table 3
Overview of IC50 values in cell lines used in research on EGFR-TKI resistance.














A549 wt >100 >100 0.01 0.003 646 Matsushima et al.
(2014),Tanizaki et al. (2011)
H292 wt >10 0.06 Chen et al. (2013b)
H358 wt KRAS codon 12 25 >10 Chen et al. (2009, 2013b)
H1299 wt 642 Tanizaki et al. (2011)
EBC1 wt MET amp 5 Tanizaki et al. (2011)
H596 wt MET exon 14del 752 Tanizaki et al. (2011)
H1437 wt MET exon 14del 1284 Tanizaki et al. (2011)
H1993 wt MET amp 10 Tanizaki et al. (2011)
H2122 wt MET N375S 472 Tanizaki et al. (2011)
HCC827 exon 19del <0.1 <0.1 0.01 767 Chen et al., (2009, 2012,
2013b), Tanizaki et al. (2011)
H1650 exon 19del 10–100 10–100 1–10 Chen et al. (2009, 2012)
PC9 exon 19del 0.03 0.02 <0.01 787 Takezawa et al. (2012),Tanizaki
et al. (2011)
PC9-GR EGFR T790M ↑ 3441 100,000 312 Yoshida et al. (2014), Kim et al.
(2012a), Lee et al. (2015), Coco
et al. (2015)
PC9-BR pHER2 ↓ pHER3
↓ pFGFR1 ↑
0.02 Azuma et al. (2014)
H3255 L858R 0.04 0.04 0.0007 Takezawa et al. (2012)
H1975 L858R/T790M 100 100 1 10 Chen et al. (2009,
2012),Matsushima et al.
(2014), Takezawa et al. (2012)
H1975-BR EMT 29 Lee et al. (2015)
PLA1 L858R/V842I >100 >100 1–10 >10 Matsushima et al. (2014)




















did not affect sensitivity in mice models (Chen et al., 2009, 2013b;
anizaki et al., 2011; Smolen et al., 2006). Thus, none of the studies
upport an effect ofmutations or deletions of theMET gene towards
KI resistance,whereas ampliﬁcation ofMET does confer resistance
o afatinib.
.3.4. STAT3 gene expression and receptor involvement in
esistance
Two cell lines carrying the T790M EGFR mutation were used to
xplore the role of STAT3 activation in the TKI-treatment induced
esistance cells (Kim et al., 2012b). Afatinib treatment induced
utocrine signaling of the JAK/STAT pathway via secretion of IL-
in H1975 and PC9-geﬁtinib resistant (GR) cells. Blocking of the
L-6 receptor pathway (IL-6R) combined with afatinib treatment
howed a more pronounced growth inhibition than afatinib alone.
ice versa, activation of the IL-6R signaling decreased sensitivity to
fatinib. Moreover, an acquired resistance to afatinib was observed
n PC9-GR xenograft mice that showed increased STAT3 protein
evels (Kim et al., 2012b). This indicates that upregulation of the
TAT3 pathway may contribute to afatinib resistance..3.5. FGFR1
The PC9-BIBW9292 (afatinib) resistant cell line (BR), showed
ecreased mRNA expression levels of HER2 and HER3 comparedto the parental PC9 cells, whereas mRNA levels of FGFR1 and its
ligand FGF2 were increased. Combining afatinib treatment with
FGFR1-siRNAs or FGFR1-TKI inhibited cell growth of PC9-BR cells
and induced a marked decrease in phosphorylation of AKT and ERK
phosphorylation (Azuma et al., 2014). Thus, this afatinib resistant
cell line was addicted to FGFR1-induced survival signals.
2.3.6. SRC family kinase (SFK)
In a tyrosine phospho-proteomic study in PC9-GR cells expres-
sion of many TKs was enhanced as compared to the wild type cells
(Yoshida et al., 2014). Another study on SFK used a combination
of dasatinib, a synthetic small molecule inhibitor of SRC-family
protein-tyrosine kinases, and afatinib. This combination overcame
the T790M mediated resistance of PC9-GR cells (IC50 of 36uM as
compared to 312uM for afatinib alone) (Huang et al., 2011). This
result was conﬁrmed in a xenograft model of nude mice injected
withPC9-GRcells. Thesedata indicate thatSFKmaypresentanother
mechanism to EGFR-TKI resistance.
2.3.7. Heat shock protein 90 (HSP90)
There are no studies in which the effect of HSP90 inhibitors has
been tested on afatinib resistant cell lines. However, in cell lines
resistant to erlotinib the combination of afatinib and the HSP90
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ndp-AKTproteins gainingmore cell death than afatinib or ganete-
pib alone (Smithet al., 2015).Ganetespib also inducedaclear effect
n CL-387,785 (pan-HER inhibitor) resistant clones or clones with
n ERBB2 exon 20 mutation (Shimamura et al., 2008, 2012). This
eans that although not studied for afatinib yet, HSP90 could play
role in treating resistance to a pan-HER inhibitor.
.3.8. Autophagy
Combined treatment of T790M positive PC9 and H1975 cells
ith afatinib and suberoylanilide hydroxamic acid (SAHA), a potent
eversible histone acetyltransferases and histone deacetylases
HDAC) inhibitor, could overcome the EGFR-TKI resistance through
ctivation of the apoptotic pathway. The enhanced apoptosis was
howntobedependenton theautophagypathway (Leeet al., 2015).
hese results were supported by in vivo data in xenograft mouse
odels.
.3.9. Upregulation of other pathways
A genome wide screen at copy number, gene expression and
rotein levels in parental and afatinib resistant subclones revealed
mongst others activation of AKT in H1975 cells (Coco et al.,
015). As activation of AKT has been associated with epithelial-
esenchymal transition (EMT) in prostate and breast cancer (Liu
t al., 2014; Yang et al., 2014), EMTcharacteristicswere also studied
n the H1975 resistant subclones. This revealed loss of E-cadherin,
ecrease in cytokeratin levels, and increased expression level of
esenchymal markers such as vimentin. Based on these ﬁndings
MT was proposed as a possible mechanism of resistance (Coco
t al., 2015). Another mode of action of inhibition of AKT may be an
ffect on the glycolytic pathway. Inhibition of the glycolysis by 2-
eoxy-d-glucose (2DG) in H1975 and PC9-GR cells potentiated the
ensitivity to afatinib. Two modes of action have been proposed.
irst, afatinib inhibits thePI3K/AKTpathwayandpreventsAKT from
witching off the glycolytic pathway providing growth-enhancing
ignals to the tumor cells. Alternatively, the emergence of resis-
ance towards afatinib lowers the AKT inhibition and switches on
he glycolytic pathway (Kim et al., 2013a; Takezawa et al., 2010).
oth mechanisms depend on the 2DG pathway, which explains the
ncreased sensitivity towards afatinib upon inhibition of the 2DG
athway. Whether NF-kB, GAS6, ADAM17, NOTCH1, Wnt, mTOR
nd p53, found to be associated with resistance to ﬁrst genera-
ion TKIs (Rosell et al., 2013; Zhang et al., 2012; Huang et al., 2011;
aumgart et al., 2010; Fong et al., 2013; Bivona et al., 2011), play
role in resistance to afatinib is not obvious, as these mechanisms
ave not been studied yet.
. Resistance after ALK tyrosine kinase inhibitors
Crizotinib is used as treatment in ALK translocation-positive
atients. Besides ALK, crizotinib also targets MET and ROS1,
lthough it has not been registered for these aberrations yet.
umors of patients treated with crizotinib become insensitive to
his drug after a median of 12 months (range: 1–34) (Shaw et al.,
013; Sequist et al., 2013). An overview of the currently proposed
nd knownmechanisms to crizotinib based on patient samples and
n in vitro data from cell line studies is discussed below.
.1. ALK inhibitor resistance in NSCLC patients
Analysis of crizotinib resistant tumor clones demonstrated new
LK gene mutations in 17 out of 53 patients, e.g. 1151Tins, L1152R,
1156Y, L1196M, S1206Y, G1269A (Table 4) (Sasaki et al., 2011;
ang et al., 2013; Katayama et al., 2012; Kim et al., 2013b; Huang
t al., 2013; Choi et al., 2010; Doebele et al., 2012). Most of these
utations affected the P-loop,-sheet or-helix of theALKprotein
n the so-called gatekeeper area. Based on the crystal structure ofcology/Hematology 100 (2016) 107–116 111
wild type and mutant (L1152R, G1202R, S1206Y and C1156Y) ALK
protein, it was predicted that mutations close to the gatekeeper
area resulted in a decreased interaction of crizotinib with the ALK
receptor. In vivo experiments conﬁrmed the accurateness of these
predictions by increased resistance to crizotinib (Sun and Ji, 2012;
Sunet al., 2013b). Thus thesegatekeepermutationspreventbinding
of crizotinib to the kinase domain of the ALK protein and due to this
the binding of crizotinib becomes ineffective.
In addition to these gatekeeper mutations, ALK copy number
gain has been found in almost 8% of resistant patients and EGFR or
KRAS mutations have also been observed in almost 8% of the resis-
tant tumor clones (Katayamaet al., 2012; Kimet al., 2013b;Doebele
et al., 2012; Jiang et al., 2013). Unusually, EGFR activating muta-
tions were observed in 3/50 EML4-ALK positive, treatment naïve
patient samples in only one study. This indicates that ALK breaks
may co-exist with EGFRmutations (Sasaki et al., 2011). However, in
large studies ALK rearrangements and EGFR activating mutations
were mutual exclusive. In another study, ampliﬁcation of KIT and
increased autophosphorylation of EGFR was observed in 2/18 re-
biopsies (Katayama et al., 2012). In some patients combinations of
multiple resistance mechanisms were observed in the same tissue
re-biopsy (Socinski et al., 2013). The data of these studies led to
the concept that tumor cells can apply both ALK dependent and
independent mechanisms to become resistant to crizotinib. In ALK
gatekeeper mutant cases, the tumor cells remain addicted to ALK
signaling. In contrast, ALK independent mechanisms refer to cases
that have become addicted to an alternative oncogene (Doebele
et al., 2012).
In clinical settings the majority of resistant mechanisms appear
to be ALK dependent, since responses are seen in up to 70% of crizo-
tinib resistant tumors on second line ALK inhibitors like ceritinib,
alectinibandbrigatinib (Table1). Thesedrugshaveahigherpotency
thereby avoiding the possibility of bypassing the ALK signaling cas-
cade via other pathways (Pall, 2015).
3.2. ALK inhibitor resistance in cell lines and xenograft mice
models
3.2.1. Gatekeeper mutations
Resistance to crizotinib has been studied in several cell lines
(Table 5). The H838 and H23 cell lines carrying wild type ALK gene
alleles, have been used as a control for the ALK break-positive cell
lines H3122, Ba/F3 and H2228 (Zhang et al., 2011). The SNU-2535
cell line carries besides an ALK break also a mutated ALK allele, i.e.
G1269A (Kim et al., 2013b). The DFCI076 cell line gained a L1152R
mutation (Sasaki et al., 2011). ALK gatekeeper mutations have been
described as the major resistance mechanism in different cell lines
treated with crizotinib. Resistant H3122 cells (H3122-CR) mainly
gained C1156Y, F1174L, L1196M and G1269A gatekeeper muta-
tions (Sasaki et al., 2011; Sang et al., 2013; Katayama et al., 2012;
Kim et al., 2013b, 2013c; Huang et al., 2013; Tanizaki et al., 2012).
The G1269A gatekeeper mutation carried by SNU-2535 and H2228
cells indeed showed increased resistance to crizotinib (Kim et al.,
2013b).
The L1152R mutation present in the patient derived DFCI076
cell line also decreased sensitivity to crizotinib (Sasaki et al., 2011).
Ba/F3 cells containing one of the three most effective resistance
inducing gatekeeper mutations, i.e. L1196M, S1206R or G1269S,
were insensitive to crizotinib in a xenograft model of SCID mice
(Zhang et al., 2011). Introduction of the T1151K, L1152V, L1152R,
C1156Y, I1171T, S1206R, E1210K, F1245C or G1269S gatekeeper
mutations in the Ba/F3 cell line by site-directed mutagenesis,
increased resistance to crizotinib by tenfold in each of the Ba/F3
subclones (Sasaki et al., 2011; Choi et al., 2010; Doebele et al., 2012;
Zhang et al., 2011). So there is solid evidence that ALK gatekeeper
mutations are involved in resistance towards crizotinib.
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Table 4
Overview of re-biopsy studies in patients treated with crizotinib.
Re-biopsy study N Mechanism mutations Technique ref
Sasaki et al. (2011) 1 ALK mutation L1152R DNA Sanger sequencing Sasaki et al. (2011)
Sang et al. (2013) 1 ALK mutation G1269A DNA Sanger sequencing
Katayama et al. (2012) 4/18 ALK mutation DNA Sanger sequencing Katayama et al. (2012)
1/18 ALK gain FISH
4/18 Higher levels of phospho-EGFR IHC
2/18 KIT ampliﬁcation Snapshot multiplexed
genotyping assay, FISH
1/18 Overexpression of KIT ligand
stem cell factor (SCF)
IHC
Kim et al. (2013) 3/7 ALK mutation L1196M, G1269A DNA Sanger sequencing Kim et al. (2013b)
1/7 ALK gain FISH
1/7 EGFR activating mutation L858R DNA Sanger sequencing




Huang et al. (2013) 3/13 ALK mutation G1269A, C1156Y, L1196M DNA Ion Torrent sequencing Huang et al. (2013)
Choi et al. (2010) 1 C1156Y, L1196M RNA paired-end sequencing of
ALK kinase domain
Choi et al. (2010)
Doebele et al. (2012) 4/11 ALK mutation L1196M, G1269A DNA direct sequencing Doebele et al. (2012)
2/11 ALK gain FISH
2/11 Loss of ALK FISH
1/11 EGFR activating mutation L858R DNA direct sequencing
2/11 KRAS mutation G12C, G12V DNA direct sequencing
Jiang et al. (2013) 1 ALK mutation G1548E Illumina Hiseq 2000 Jiang et al. (2013)
Table 5
Overview of IC50 in cell lines used in research on crizotinib resistance.
Cell line Alterations Crizotinib(uM) ref
ALK other
H23 wt 1.7 Zhang et al. (2011)
H838 wt 1.3 Zhang et al. (2011)
H2228 ALK-EML4 0.01 Zhang et al. (2011), Kim et al. (2013c)
H2228-CR EGFR ↑ BIM ↓ 0.3 Kim et al. (2013c)
H3122 ALK-EML4 0.07–0.19 Sasaki et al. (2011), Sang et al. (2013), Katayama et al. (2012), Huang
et al. (2013), Kim et al. (2013c), Tanizaki et al. (2012), Yamaguchi et al.
(2014), Ji et al. (2014)
H3122-CR Gatekeeper mutationsa 0.24–0.26 Sasaki et al. (2011), Sang et al. (2013), Katayama et al. (2012), Huang
et al. (2013), Kim et al. (2013c), Tanizaki et al. (2012), Yamaguchi
et al.,(2014), Ji et al. (2014)
H3122-CR F1174L 0.62 Sasaki et al. (2011)
H3122-CR1 EMT >3 Sang et al. (2013), Ji et al. (2014)
H3122-TR EGFR ↑ 2.56 Sasaki et al., (2011), Kim et al. (2013c)
DFCI076 ALK-EML4, L1152R 1.01 Sasaki et al. (2011)
Ba/F3 ALK-ELM4 0.02–0.07 Sasaki et al. (2011), Katayama et al. (2012), Choi et al. (2010), Doebele
et al. (2012), Zhang et al. (2011)
Ba/F3 Gatekeeper mutationsb 0.2–0.9 Sasaki et al. (2011), Katayama et al. (2012), Choi et al. (2010), Doebele
et al. (2012), Zhang et al. (2011)
SNU-2535 ALK-EML4, G1269A 8 Kim et al. (2013b)
wt: wild type.
a C1156Y, L1196M, G1269A, L1152R.












Activation of the EGFR signaling pathway, as another mecha-
ismof resistance toALK inhibitors,wasdemonstrated in subclones
fH3122 treatedwithcrizotinib. Treatmentof theseH1322-CRcells
ith EGFR-TKI resulted in inhibition of cell growth (Tanizaki et al.,
012; Yamaguchi et al., 2014). Treatment of nude mice injected
ith H2228 NSCLC cells that overexpress the EML4-ALK fusion pro-
ein with crizotinib resulted in resistant xenografts that showed
pregulation of the EGFR signaling pathway. These xenografts
ppeared to be sensitive to a combination of crizotinib and ganete-
pib. Ganetespib inhibits different HSP90 clients, including EGFR
nd may thus target the EGFR resistance associated activation inthese cells and explain the enhanced sensitivity to the combined
treatment. HSP90 inhibitors also directly have impact on ALK sta-
bility and therefore they are used to treat ALK resistant patients.
Functional loss of the signaling cascades was also associated with
increased BIM protein expression. Based on these ﬁndings the
authors suggested that BIM and EGFR upregulation, without acti-
vating mutations, is associated with crizotinib resistance (Sang
et al., 2013).3.2.3. Autophagy
Another mechanism proposed in H3122-CR cells was the
induction of autophagy. Inhibition of the autophagy pathway by
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Fig. 1. Overview of probable resistance mechanisms in EGFR-TKI afatinib.
Legend: Proven resistance mechanisms include gatekeeper mutations (1) and MET ampliﬁcation (2). The V843I mutation is a proven mechanism of resistance while this is
most likely not the case for the T790M mutation. MET ampliﬁcation is a proven resistance mechanism, but MET mutations probably not. All other proposed mechanisms
(3–7) need to be studied in more detail to proof their causal resistance in patient samples. FGFR1 ampliﬁcation (3), IL-6R/JAK1/STAT3 pathway (4) and autophagy (7) have
been associated with resistance. The glycolysis pathway (5) induced by AKT has been proposed, although it is not clear why resistance occurs. Src upregulation (6) has been
associated with resistance. Dashed arrow inhibited pathway, solid line arrow induced pathway.
Fig. 2. Overview of possible resistance mechanism induced upon treatment with the ALK inhibitor crizotinib.
Legend: The only proven resistance mechanisms is gain of ALK gatekeeper mutations (1) due to lower binding efﬁciency of crizotinib. Other possible resistance mechanisms









cutations (3) have been found in patients treated with afatinib; autophagy (4) has
een found in resistant cell lines to crizotinib. Possible clinical relevance of these m
athway.
hloroquine and baﬁlomycin showed increased sensitivity to crizo-
inib (Ji et al., 2014). However, the clinical relevance of autophagy
n the development of crizotinib resistance is not known..2.4. Epithelial-mesenchymal transition (EMT)
Phenotypical alterations of the cell morphology due to down-
egulation of E-cadherin and AXL and upregulation of vimentin are
haracteristics of EMT that have also been implicated in crizotinibfound in a crizotinib resistant cell line; epithelial-mesenchymal transition (5) has
nisms are not clear yet. Dashed arrow inhibited pathway, solid line arrow induced
resistance. H2228 crizotinib resistant cells did not have secondary
mutations, but did show epithelial-mesenchymal transition (EMT).
EMT induced by TGF-1 revealed resistance to crizotinib in lung
cancer cell lines that was reversible by removal of the TGF-.
Suppression of vimentin in H2228-CR cells by siRNA treatment
restored sensitivity to crizotinib (Kim et al., 2013c). Thus, EMT
may be a mechanism of resistance to crizotinib treatment as
well.
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. Concluding remarks
Afatinib, erlotinib and geﬁtinib are the main drugs used to tar-
et EGFR and crizotinib is the main drug to target ALK. Alternative
KIs are still under investigation in clinical studies. For EGFR, the
790M mutation is important in the development of resistance
o reversible TKI. The current literature is contradictory about its
ole in irreversible EGFR blocking agents such as afatinib. Clini-
al relevant concentrations for afatinib (0.08M) and dacomitinib
0.04M) are much lower than those for both erlotinib (4M) and
eﬁtinib (0.9M) (Goss et al., 2005; Hidalgo et al., 2001; Bello et al.,
013; Yap et al., 2010). In relation to the effective dose required to
nhibit cell growth of T790M positive lung cancer cell lines, it is
nlikely that clinical effects will be achieved with the EGFR-TKIs in
atients with a secondary T790M mutation. Similar, there is also
o support for a role of HER2 ampliﬁcation, although this has been
bserved as a resistance mechanism after ﬁrst generation TKI. This
s probably due to the fact that afatinib is a HER2 inhibitor as well.
ne of the most evident afatinib resistance mechanisms is ampliﬁ-
ation ofMET (Fig. 1). Current studies indicate that resistance is not
ell associated with MET mutations or positive MET protein stain-
ng. TheV843Imutation affecting binding of afatinib to EGFR causes
esistance at least in cell lines. Overexpression of FGFR1, increased
L6R/JAK/STAT signaling, enhanced interference with the aerobic
lycolysis, autophagy and SFK all have been associated with resis-
ance to afatinib in one ormore lung cancer cell lines. Until now, for
fatinib the only proven resistance mechanisms include the V843I
utation andMET ampliﬁcation (Fig. 1). Othermechanisms studied
nly in cell lines need to be conﬁrmed in afatinib resistant tumor
amples.
The main mechanism of crizotinib resistance is gain of a gate-
eeper mutation leading to less effective binding of crizotinib to
he mutated ALK kinase domain (Fig. 2). This has been shown in
oth patient samples and in cell lines. As only 40% of patients with
linical resistance have such gatekeeper mutations, there have to
e other mechanisms in the remaining 60% of patients. Analysis
f re-biopsies of patients upon crizotinib resistance revealed ALK
mpliﬁcations,EGFRandKRASmutations. The causalnatureof these
utations needs to be conﬁrmed and in a signiﬁcant proportion of
he patients the resistance mechanism remains unknown. Alter-
ative mechanisms studied only in lung cancer cell lines include
ctivation of the EGFR pathway, induction of the autophagy path-
ay and EMT. So, besides ALK gatekeeper mutations, all other
roposed resistance mechanisms need to be studied in more detail
o either proof the real cause of the observed resistance and
hether these mechanisms also really determine resistance in
atients treated with crizotinib in vivo.
.1. Future perspectives
It is evident that in depth studies on the proposed resistance
echanisms are required to elucidate the full spectrumof TKI resis-
ance. The discrepancy between clinical and cell line or xenograft
esults are due to the small therapeutic index of second genera-
ion EGFR TKI, such as afatinib. Clinical achievable doses of EGFR
KIs providing a balance between efﬁcacy and side effects were
oo low to suppress T790M efﬁciently in EGFR mutant patients.
nother known strategy to overcome resistance is to use a TKI
rug holiday. During this drug holiday patients receive cytotoxic
hemotherapy. After progression on this treatment, a re-challenge
f TKIs can be given with the same TKI as used in ﬁrst line, indi-
ating that the initial resistance is not caused by mutations (Becker
t al., 2011). Prospective studies are currently being performed to
eﬁne response rates using this strategy. Beside this, next gen-
ration TKIs have been developed to overcome resistance. Those
mallermolecules ﬁt better in the functional tyrosine kinase pocketncology/Hematology 100 (2016) 107–116
than in the wild type pocket, e.g. osimertinib and rociletinib for
EGFR mutation positive cases and ceritinib, alectinib, brigatinib
and lorlatinib for ALK translocations (Jänne et al., 2015; Sequist
et al., 2015; Pall, 2015; Mehra et al., 2012; Shaw et al., 2015). The
renewed sensitivity towards TKIs after a drug holiday may support
a role of epigenetic mechanisms, however these mechanisms have
not been studied yet for the TKIs discussed here in lung cancer. A
study with the HDAC inhibitor entinostat showed that a subgroup
of patients with EMT had an advantage in OS. Therefore, further
biomarker studies are needed to deﬁnewhichpatientswill respond
to adding HDAC inhibitors (Witta et al., 2012). Resistance to EGFR-
TKIs is associated with a BIM deletion polymorphism in cell lines.
HDAC vorinostat restored the cell death pathway in cell lines with
the BIM deletion and overcame resistance to geﬁtinib (Nakagawa
et al., 2013).Moreover,HDAC inhibitors in combinationwithHSP90
inhibitors have a synergistic effect on inhibition of growth of TKI
resistant cell lines (Sunet al., 2013b). This combinationhasnotbeen
tested in a clinical setting yet. Next generation sequencing of resis-
tant tumor samples and functional studies of observed recurrent
alterations can help to explain the complex pattern of resistance
after exposure towards TKI. Current studies suggest involvement
of multiple pathways as possible resistance mechanisms and these
should be functionally tested in cell lines to prove a causal relation.
Novel gene editing techniques such as CRISPR-cas and TALENSmay
speed up elucidation of speciﬁc resistance mechanisms in cell lines
that can be validated in patient derived xenografts for the different
EGFR-TKIs and ALK inhibitors. Efﬁcacy studies using combination
therapy to prevent resistance to TKI may be a promising strategy
for future clinical trials. Moreover, new therapeutic strategies are
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